TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02519543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be given twice daily, once with breakfast and once with supper

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Active experimental drug to be given twice a day, 1000 mg with breakfast and 1000 mg with supper
Study: NCT04496037

Intervention type: DRUG
Intervention: Rituximab
Description: See NCT03994783
Study: NCT00966628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic sodium lactate
Description: Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
Study: NCT01026857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine
Description: PLC colon release tablet 1 g/die for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine
Description: PLC colon release tablet 2 g/die for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo PLC colon release tablet 2 g/die for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo PLC colon release tablet 2 g/die for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PLC colon release tablet 2 g/die for 4 weeks
Study: NCT04915222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural apophyseal glides
Description: Patients received conventional therapy and NAGS with 2-3 hertz (less than 6 repetitions) in 3 sets for 3 weeks. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical manual traction
Description: Patients received cervical manual traction (CMT) along with traditional therapy. Treatment frequency was 3 sessions per week for total three weeks duration. CMT applied was intermittent type traction.8 to 10 kg force was applied at an angle of 20 to 25 degree from horizontal. 5sets of cervical traction are performed. In every set traction is given for 1 minute with rest period of 20 seconds. The total time of traction session was 10 minute. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
Study: NCT01956565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle training
Description: Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
Study: NCT03209167

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Two study-specific questionnaires

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Two study-specific questionnaires
Study: NCT00913536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using Cone beam CT in patients with Bladder Cancer
Description: Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
Study: NCT02297087

Intervention type: GENETIC
Group type: OTHER
Intervention: Standard of care based on target(s) identified via GWS.
Study: NCT01397669

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colon biopsy, lymph node biopsy, lumbar puncture, Leukapheresis, Brain MRI/MRS/DTI
Description: Eligible subjects will undergo a flexible sigmoidoscopy/biopsy and Brain MRI/MRS/DTI at Chulalongkorn University Hospital.~Lumbar puncture, lymph node biopsy, and leukapheresis will be done at TRCARC or IHRI.
Study: NCT03735901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMP Levodopa 100mg/Carbidopa 25mg
Description: Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Study treatment will comprise 3 phases:~1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning.
Study: NCT03635996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil NS 70 mg
Description: All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Pharma Nasal Spray Bidose System
Description: Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.
Study: NCT03092011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
Study: NCT01744366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Study: NCT00165308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given orally, daily for one year.
Study: NCT02290574

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperthermia with concurrent chemo-radiation therapy
Study: NCT01337505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INNO-206
Description: INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
Study: NCT02346812

Intervention type: OTHER
Group type: OTHER
Intervention: Controlled diet without brassica vegetables
Description: Participants will be fed a controlled diet containing foods of a typical American diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled diet with brassica vegetables
Description: Participants will be fed a controlled diet containing foods of a typical American diet.
Study: NCT00107614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT PACE + Rituxan
Description: INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with \< 50% response to induction) OR MEL-DT PACE (Patients with \> 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
Study: NCT02755883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity plus positive affect
Description: Subjects will be randomized to a physical activity goal and will receive the positive affect component.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity plus education
Description: Subjects will be randomized to a physical activity goal and will receive the educational component.
Study: NCT01048359

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention plus Booster
Description: A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: A brief drug use intervention based on motivational interviewing is provided to participants at baseline
Study: NCT03939065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor Augmented Pump Therapy
Description: Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care with CGM
Description: Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
Study: NCT02465814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670
Description: Placebo (12 weeks),Vilaprisan (12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670
Description: Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal
Description: Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
Study: NCT02385214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide Local Excision = 1cm Margin
Description: A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide Local Excision = 2cm Margin
Description: A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery.
Study: NCT02719327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icosapent ethyl (IPE)
Description: Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gel cap placebo
Description: Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
Study: NCT03029702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin will be used for GDM treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin will be used for GDM treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Glyburide will be used for GDM treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Glyburide will be used for GDM treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be used for GDM treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be used for GDM treatment
Study: NCT04282278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab/sintilimab+ Standard chemotherapy
Description: Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）
Description: Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Apatinib：250mg，d1，qd，po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy
Description: Camrelizumab/sintilimab：200mg，iv，30min，d7，q3w，24 months Apatinib：250mg，d1，qd，po Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
Study: NCT03200158

Intervention type: OTHER
Group type: OTHER
Intervention: Endoscopy biopsy and blood
Description: Medical operation
Study: NCT01479504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin and docetaxel
Description: neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin and docetaxel
Description: neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin and docetaxel
Description: neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin and docetaxel
Description: neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy
Study: NCT02465814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal
Description: Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
Study: NCT02254278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m2 IV (intravenously) weekly for 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT 6 weeks
Description: Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT 5 weeks
Description: Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy
Study: NCT02353754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine injection
Description: 0.2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: 266 mg
Study: NCT03851133

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date) and at the time of follow-up (approximately 6 months and approximately 12 months after baseline).

Intervention type: OTHER
Intervention: Tumor Sample collection
Description: At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue and tissue from site of metastasis will be collected.

Intervention type: OTHER
Intervention: Data Collection
Description: Participants will be asked to complete a 3 page screening tool at the time of their in-person clinic visit, as well as questionnaires at baseline and at 6 and 12 months.
Study: NCT01941914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium chloride
Study: NCT02465814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal
Description: Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
Study: NCT03913286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortimo
Description: The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.
Study: NCT02098603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Testing & Intervention
Description: Intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, 30 minute weekly sessions incorporated into a team's usual work time or overtime activities.
Study: NCT01428713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral tranexamic acid
Description: Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive Pills
Description: Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
Study: NCT02002858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression and Anxiety Smoking Cessation Treatment
Description: Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
Study: NCT03335111

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Remote Ischemic Conditioning Equipment
Description: BAIPC is admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation) for one week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous blood collection
Description: Nurses will collect 5 ml intravenous blood with anticoagulant and 5ml total blood at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
Study: NCT03145077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03335111

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intravenous blood collection
Description: Nurses will collect 5 ml intravenous blood with anticoagulant and 5ml total blood at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
Study: NCT03145077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02367989

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0g barley β-glucan no fibre
Description: Food containing no barley β-glucan and no additional fibre

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2g barley β-glucan
Description: Food containing low amounts of barley β-glucan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4g barley β-glucan
Description: Food containing medium amounts of barley β-glucan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6g barley β-glucan
Description: Food containing high amounts of barley β-glucan
Study: NCT03145077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies